• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org

Blog

survey iweb1
Global NET patient survey

The International Neuroendocrine Cancer Alliance (INCA) and Novartis presents the quality-of-life results from the first global survey of patients with neuroendocrine tumors (NETs), a rare type of cancer1.

Nearly 2,000 patients from 12 countries completed the survey, which was a collaborative effort between INCA and Novartis. The results were presented at a medical meeting and provide compelling data documenting the impact of NETs on people living with this disease1. These quality-of-life findings are the first in a series of results from the survey being released in conjunction with Worldwide NET Cancer Awareness Day (WNCAD), November 10.

Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button